Nucleic acid vaccines: Prospects for non-viral delivery of mRNA vaccines

Expert Opinion on Drug Delivery

Volumn 11, Issue 6, 2014, Pages 885-899

  Deering, Raquel P ^a   Kommareddy, Sushma ^a   Ulmer, Jeffrey B ^a   Brito, Luis A ^a   Geall, Andrew J ^a  

^a Novartis Vaccines Inc   (United States)

Author keywords

Delivery system; Mode of action; mRNA; Vaccine

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; LIPOPLEX; LIPOSOME; MESSENGER RNA VACINE; NANOCARRIER; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; UNCLASSIFIED DRUG; VACCINE;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; DENDRITIC CELL; DRUG HALF LIFE; ELECTROPORATION; ENDOCYTOSIS; GENE EXPRESSION; GENE GUN; HOST CELL; HUMAN; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KIDNEY CARCINOMA; MACROPHAGE; METASTATIC MELANOMA; MONOCYTE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OPEN READING FRAME; PATTERN RECOGNITION; PROSTATE CANCER; PURIFICATION; REVIEW; RNA DEGRADATION; RNA STABILITY; RNA VIRUS; SEMLIKI FOREST ALPHAVIRUS; SIGNAL TRANSDUCTION; SINDBIS VIRUS; TRANSLATION INITIATION; TREATMENT RESPONSE; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRUS REPLICATION;

DELIVERY SYSTEM; MODE OF ACTION; MRNA; VACCINE;

ANIMALS; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; PLASMIDS; RNA, MESSENGER; VACCINES, DNA;

EID: 84901249588     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2014.901308     Document Type: Review

References (118)

1. Rappuoli R, Mandl CW, Black S, De Gregorio E. Vaccines for the twenty-first century society. Nat Rev Immunol 2001;11:865-72
2. Koff WC, Burton DR, Johnson PR, et al. Accelerating next-generation vaccine development for global disease prevention. Science 2013;340:1232910
3. Liu MA. Immunologic basis of vaccine vectors. Immunity 2010;33:504-15
4. Ferraro B, Morrow MP, Hutnick NA, et al. Clinical applications of DNA vaccines: Current progress. Clin Infect Dis 2011;53:296-302
5. Liu MA. DNA vaccines: An historical perspective and view to the future. Immunol Rev 2011;239:62-84
6. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012;30:4414-18
7. Geall AJ, Mandl CW, Ulmer JB. RNA: The new revolution in nucleic acid vaccines. Semin Immunol 2013;25:152-9
8. Kallen KJ, Heidenreich R, Schnee M, et al. A novel, disruptive vaccination technology: Self-Adjuvanted RNActive vaccines. Hum Vaccin Immunother 2013;9:2263-76
9. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004;4:1285-94
10. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008;183:221-35
11. Pollard C, De Koker S, Saelens X, et al. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med 2013;19:705-13
12. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8
13. Weiner DB. RNA-based vaccination: Sending a strong message. Mol Ther 2013;21:506-8
14. Ye JD, Tereshko V, Frederiksen JK, et al. Synthetic antibodies for specific recognition and crystallization of structured RNA. Proc Natl Acad Sci USA 2008;105:82-7
15. Buneva VN, Krasnorutskii MA, Nevinsky GA. Natural antibodies to nucleic acids. Biochemistry (Moscow) 2013;78:127-43
16. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-9
17. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77
18. Van Lint S, Heirman C, Thielemans K, Breckpot K. mRNA: From a chemical blueprint for protein production to an off-The-shelf therapeutic. Hum Vaccines Immunother 2013;9:265-74
19. Boudreau JE, Bonehill A, Thielemans K, Wan Y. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 2011;19:841-53
20. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: Genetic modification of dendritic cells. J Gene Med 2004;6:1175-88 (Pubitemid 40228129
21. Van Tendeloo VF, Ponsaerts P, Berneman ZN. mRNA-based gene transfer as a tool for gene and cell therapy. Curr Opin Mol Ther 2007;9:423-31 (Pubitemid 47574618
22. Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-Amplifying RNA vaccines. Proc Natl Acad Sci USA 2012;109:14604-9
23. Barrett LW, Fletcher S, Wilton SD. Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci 2012;69:3613-34
24. Chatterjee S, Pal JK. Role of 5¢- And 3¢-untranslated regions of mRNAs in human Diseases. Biol Cell 2009;101:251-62
25. Pickering BM, Willis AE. The implications of structured 5¢ untranslated regions on translation and disease. Semin Cell Dev Biol 2005;16:39-47 (Pubitemid 40126875
26. Ross J. mRNA stability in mammalian cells. Microbiol Rev 1995;59:423-50
27. Gingras AC, Raught B, Sonenberg N. eIF4 initiation factors: Effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem 1999;68:913-63 (Pubitemid 29449212
28. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol 2012;9:1319-30
29. Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008;10:e33
30. Lundstrom K. Alphavirus vectors: Applications for DNA vaccine production and gene expression. Intervirology 2000;43:247-57 (Pubitemid 32225696
31. Schlesinger S. Alphavirus vectors: Development and potential therapeutic applications. Expert Opin Biol Ther 2001;1:177-91 (Pubitemid 33770075
32. Smerdou C, Liljestrom P. Non-viral amplification systems for gene transfer: Vectors based on alphaviruses. Curr Opin Mol Ther 1999;1:244-51 (Pubitemid 29238428
33. Uematsu Y, Vajdy M, Lian Y, et al. Lack of interference with immunogenicity of a chimeric alphavirus replicon particlebased influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol 2012;19:991-8
34. Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. J Immunother 2008;31:180-8
35. Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: Results of a phase 1/ 2 vaccination trial in metastatic melanoma patients. J Immunother 2009;32:498-507
36. Rittig SM, Haentschel M, Weimer KJ, et al. Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients. Mol Ther 2011;19:990-9
37. Fotin-Mleczek M, Zanzinger K, Heidenreich R, et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med 2012;14:428-39
38. Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009;28:484-93
39. Benvenisty N, Reshef L. Direct introduction of genes into rats and expression of the genes. Proc Natl Acad Sci USA 1986;83:9551-5 (Pubitemid 17223396
40. Nicolau C, Le Pape A, Soriano P, et al. In vivo expression of rat insulin after intravenous administration of the liposome-entrapped gene for rat insulin I. Proc Natl Acad Sci USA 1983;80:1068-72
41. Soriano P, Dijkstra J, Legrand A, et al. Targeted and nontargeted liposomes for in vivo transfer to rat liver cells of a plasmid containing the preproinsulin I gene. Proc Natl Acad Sci USA 1983;80:7128-31 (Pubitemid 14207367
42. Kopycinski J, Cheeseman H, Ashraf A, et al. A DNA-based candidate HIV vaccine delivered via in vivo electroporation induces CD4 responses toward the alpha4beta7-binding V2 loop of HIV gp120 in healthy volunteers. Clin Vaccine Immunol 2012;19:1557-9
43. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6:e19252
44. Daud AI, DeConti RC, Andrews S, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008;26:5896-903
45. Semple SC, Akinc A, Chen J, et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010;28:172-6
46. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: Advances in siRNA delivery. Nat Ren Drug Discov 2009;8:129-38
47. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010;107:1864-9
48. Kormann MS, Hasenpusch G, Aneja MK, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat Biotechnol 2011;29:154-7
49. Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction. Nat Biotechnol 2013;31:898-907
50. Uzqün S, Nica G, Pfeifer C, et al. PEGylation improves nanoparticle formation and transfection efficiency of messenger RNA. Pharm Res 2011;28:2223-32
51. Weiss R, Scheiblhofer S, Roesler E, et al. mRNA vaccination as a safe approach for specific protection from type I allergy. Expert Rev Vaccines 2012;11:55-67
52. Zhang Z, Satterlee A, Huang L. In vivo gene delivery by nonviral vectors: Overcoming hurdles?. Mol Ther 2012;20:1298-304
53. Schott JW, Galla M, Godinho T, et al. Viral and Non-Viral Approaches for Transient Delivery of mRNA and Proteins. Curr Gene Ther 2011;11:382-98
54. Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010;70:9031-40
55. Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012;72:1661-71
56. Petsch B, Schnee M, Vogel AB, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012;30:1210-16
57. Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011;34:1-15
58. Scheel B, Teufel R, Probst J, et al. Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. Eur J Immunol 2005;35:1557-66 (Pubitemid 40691436
59. Hecker JG. Nonviral, cationic lipid-mediated delivery of mRNA. Methods Mol Biol 2013;969:73-88
60. Zou S, Scarfo K, Nantz MH, Hecker JG. Lipid-mediated delivery of RNA is more efficient than Delivery of DNA in non-dividing cells. Int J Pharm 2010;389:232-43
61. Anderson DM, Hall LL, Ayyalapu AR, et al. Stability of mRNA/cationic lipid lipoplexes in human and rat cerebrospinal fluid: Methods and evidence for nonviral mRNA gene delivery to the central nervous system. Hum Gene Ther 2003;14:191-202 (Pubitemid 36423439
62. Uchida S, Itaka K, Uchida H, et al. Messenger RNA introduction into the central nervous system using polyplex nanomicelle. PLoS One 2013;8:e56220
63. Pollard C, Rejman J, De Haes W, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 2013;21:251-9
64. Perche F, Benvegnu T, Berchel M, et al. Enhancement of dendritic cells transfection in vivo and of vaccination against B16F10 melanoma with mannosylated histidylated lipopolyplexes loaded with tumor antigen messenger RNA. Nanomedicine 2011;7:445-53
65. Martinon F, Krishnan S, Lenzen G, et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposomeentrapped mRNA. Eur J Immunol 1993;23:1719-22 (Pubitemid 23218089
66. Fleeton MN, Chen M, Berglund P, et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001;183:1395-8 (Pubitemid 32337123
67. Johanning FW, Conry RM, LoBuglio AF, et al. A Sindbis virus mRNA polynucleotide vector achieves prolonged and high level heterologous gene expression in vivo. Nucleic Acids Res 1995;23:1495-501
68. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev Med Virol 2002;12:279-96
69. Perri S, Greer CE, Thudium K, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003;77:10394-403 (Pubitemid 37129683
70. Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010;70:9031-40
71. Carralot JP, Probst J, Hoerr I, et al. Polarization of immunity induced by direct injection of naked sequencestabilized mRNA vaccines. Cell Mol Life Sci 2004;61:2418-24 (Pubitemid 39382031
72. Kofler RM, Aberle JH, Aberle SW, et al. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci USA 2004;101:1951-6 (Pubitemid 38228996
73. Mandl CW, Aberle JH, Aberle SW, et al. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model. Nat Med 1998;4:1438-40
74. Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PLoS One 2012;7:e29732
75. Piggott JM, Sheahan BJ, Soden DM, et al. Electroporation of RNA stimulates immunity to an encoded reporter gene in mice. Mol Med Rep 2009;2:753-6
76. Cu Y, Broderick K, Banerjee K, et al. Enhanced delivery and potency of selfamplifying mRNA vaccines by electroporation in situ. Vaccines 2013;1:367-83
77. Love KT, Mahon KP, Levins CG, et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci USA 2010;107:1864-9
78. Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM- vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect 2013;2:e52
79. Lorenz C, Fotin-Mleczek M, Roth G, et al. Protein expression from exogenous mRNA: Uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway. RNA Biol 2011;8:627-36
80. Dominska M, Dykxhoorn DM. Breaking down the barriers: SiRNA delivery and endosome escape. J Cell Sci 2010;123:1183-9
81. Glover DJ. Artificial viruses: Exploiting viral trafficking for therapeutics. Infect Disord Drug Targets 2012;12:68-80
82. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-20
83. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature 2001;413:732-8 (Pubitemid 33009951
84. Wilkins C, Gale M Jr. Recognition of viruses by cytoplasmic sensors. Curr Opin Immunol 2010;22:41-7
85. Kumar H, Kawai T, Akira S. Pathogen recognition by the innate immune system. Int Rev Immunol 2011;30:16-34
86. Kawai T, Akira S. Antiviral signaling through pattern recognition receptors. J Biochem 2007;141:137-45 (Pubitemid 46775751
87. Shedlock DJ, Weiner DB. DNA vaccination: Antigen presentation and the induction of immunity. J Leukoc Biol 2000;68:793-806
88. Hemmi H, Akira S. TLR signalling and the function of dendritic cells. Chem Immunol Allergy 2005;86:120-35 (Pubitemid 40905001
89. Wilgenhof S, Van Nuffel AM, Benteyn D, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013;24:2686-93
90. Warren L, Manos PD, Ahfeldt T, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30
91. Kariko K, Weissman D. Naturally occurring nucleoside modifications suppress the immunostimulatory activity of RNA: Implication for therapeutic RNA development. Curr Opin Drug Discon Devel 2007;10:523-32 (Pubitemid 47367766
92. Yoshioka N, Gros E, Li HR, et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. Cell Stem Cell 2013;13:246-54
93. Kielian M, Rey FA. Virus membranefusion proteins: More than one way to make a hairpin. Nat Rev Microbiol 2006;4:67-76 (Pubitemid 43135288
94. Brown DT, Hernandez R. Infection of cells by alphaviruses. Adv Exp Med Biol 2012;726:181-99
95. Vancini R, Wang G, Ferreira D, et al. Alphavirus genome delivery occurs directly at the plasma membrane in a time- And temperature-dependent process. J Virol 2013;87:4352-9
96. Paredes AM, Ferreira D, Horton M, et al. Conformational changes in Sindbis virions resulting from exposure to low pH and interactions with cells suggest that cell penetration may occur at the cell surface in the absence of membrane fusion. Virology 2004;324:373-86 (Pubitemid 38797854
97. Dimitron DS. Virus entry: Molecular mechanisms and biomedical applications. Nat Rev Microbiol 2004;2:109-22 (Pubitemid 39490065
98. Froshauer S, Kartenbeck J, Helenius A. Alphavirus RNA replicase is located on the cytoplasmic surface of endosomes and lysosomes. J Cell Biol 1988;107:2075-86 (Pubitemid 19015087
99. Kujala P, Ikaheimonen A, Ehsani N, et al. Biogenesis of the Semliki Forest virus RNA replication complex. J Virol 2001;75:3873-84 (Pubitemid 32246396
100. Rejman J, Bragonzi A, Conese M. Role of clathrin- And caveolae-mediated endocytosis in gene transfer mediated by lipo- And polyplexes. Mol Ther 2005;12:468-74 (Pubitemid 41150132
101. Ruthardt N, Lamb DC, Brauchle C. Single-particle tracking as a quantitative microscopy-based approach to unravel cell entry mechanisms of viruses and pharmaceutical nanoparticles. Mol Ther 2011;19:1199-211
102. Jarve A, Muller J, Kim IH, et al. Surveillance of siRNA integrity by FRET imaging. Nucleic Acids Res 2007;35:e124
103. Probst J, Weide B, Scheel B, et al. Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion Dependent. Gene Ther 2007;14:1175-80 (Pubitemid 47086748
104. Martinez-Gil L, Goff PH, Hai R, et al. A Sendai virus-derived RNA agonist of RIG-I as a virus vaccine adjuvant. J Virol 2013;87:1290-300
105. Pichlmair A, Kandasamy K, Alvisi G, et al. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature 2012;487:486-90
106. Graham RL, Becker MM, Eckerle LD, et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 2012;18:1820-6
107. Bettinger T, Carlisle RC, Read ML, et al. Peptide-mediated RNA delivery: A novel approach for enhanced transfection of primary and post-mitotic cells. Nucleic Acids Res 2001;29:3882-91 (Pubitemid 32910528
108. Huth S, Hoffmann F, von Gersdorff K, et al. Interaction of polyamine gene vectors with RNA leads to the dissociation of plasmid DNA-carrier complexes. J Gene Med 2006;8:1416-24 (Pubitemid 46040649
109. Wang Y, Su HH, Yang Y, et al. Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy. Mol Ther 2013;21:358-67
110. Fahmy TM, Demento SL, Caplan MJ, et al. Design opportunities for actively targeted nanoparticle vaccines. Nanomedicine 2008;3:343-55 (Pubitemid 351827311
111. Kreiter S, Diken M, Selmi A, et al. Tumor vaccination using messenger RNA: Prospects of a future therapy. Curr Opin Immunol 2011;23:399-406
112. Kaslow DC. A potential disruptive technology in vaccine development: Gene-based vaccines and their application to infectious diseases. Trans R Soc Trop Med Hyg 2004;98:593-601 (Pubitemid 39345160
113. Kutzler MA, Weiner DB. DNA vaccines: Ready for prime time?. Nat Rev Genet 2008;9:776-88
114. Hoerr I, Obst R, Rammensee HG, Jung G. In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol 2000;30:1-7
115. Rettig L, Haen SP, Bittermann AG, et al. Particle size and activation threshold: A new dimension of danger signaling. Blood 2010;115:4533-41
116. Steitz J, Britten CM, Wolfel T, Tuting T. Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2. Cancer Immunol Immunother 2006;55:246-53 (Pubitemid 41682573
117. Su X, Fricke J, Kavanagh DG, Irvine DJ. In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles. Mol Pharm 2011;8:774-87
118. Charlotte P, Joanna R, Winni De H, et al. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Mol Ther 2012;21:251-9